Why the study?
Does triflusal reduce the incidence of nonfatal ischemic stroke, nonfatal acute myocardial infarction, or vascular death compared to aspirin in patients with stroke or transient ischemic attack?
Population
2,113 patients with stroke or transient ischemic attack (TIA)
Comparison
Triflusal 600 mg/d vs Aspirin 325 mg/d
Design
RCT, randomized, double-blind
Follow-up
mean 30.1 months
Authors
Loading...
Triflusal matches aspirin for secondary prevention after stroke/TIA with fewer major hemorrhages; extends safer antiplatelet options for high-bleeding-risk patients.
Does triflusal reduce the incidence of nonfatal ischemic stroke, nonfatal acute myocardial infarction, or vascular death compared to aspirin in patients with stroke or transient ischemic attack?
Triflusal is not superior to aspirin for long-term secondary prevention of vascular events after stroke or TIA, but it offers a significantly better safety profile regarding hemorrhagic complications.
Daoming Tong (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: